STOCK TITAN

Innovent Biolgcs (IVBIY) Stock News, Mar-May 2024

IVBIY OTC

Innovent Biologics, Inc. develops, manufactures and commercializes biopharmaceutical medicines for oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas. News from Innovent centers on product approvals and commercial updates in China, clinical and preclinical data for pipeline assets, medical-congress presentations, and partner-reported development updates. Recurring drug and program references include mazdutide for type 2 diabetes, IBI363 in cancer immunotherapy, IBI324/OLN324 for retinal disease, tigulixostat/IBI128 for gout, and immunology assets such as picankibart/IBI112, IBI3013 and IAR129.

Rhea-AI Summary

Innovent Biologics, Inc. receives NMPA Breakthrough Therapy Designation for IBI343 as monotherapy for advanced gastric cancer. The designation is based on promising Phase 1 study results showing safety, tolerability, and antitumor activity in advanced GC patients. Innovent plans to conduct a Phase 3 clinical trial soon. The company aims to provide effective third-line treatment options for GC patients in need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Innovent Biologics, Inc. appoints Dr. Samuel Zhang as Global Chief Business Officer, bringing over 20 years of industry experience. Dr. Zhang will lead global strategy and business development, reporting to Dr. Michael Yu. His expertise includes identifying industry trends, R&D decision-making, and strategic transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences clinical trial
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences clinical trial

FAQ

What is the current stock price of Innovent Biolgcs (IVBIY)?

Innovent Biolgcs (IVBIY) last closed at $43.34.

What is the market cap of Innovent Biolgcs (IVBIY)?

The market cap of Innovent Biolgcs (IVBIY) is approximately $18.9B.